CRSP News and Press, CRISPR Therapeutics AG From 03/02/26

2026-03-02 12:20:00 ET CRISPR Therapeutics (NASDAQ: CRSP) is a company that can potentially help revolutionize healthcare. Its gene-editing therapies can be game changers for patients living with illnesses and conditions that might otherwise be difficult to treat. The company al...

2026-02-28 15:15:29 ET More on related tickers, etc. PayPal: A Textbook Value Trap TopBuild Corp. 2025 Q4 - Results - Earnings Call Presentation PayPal's Treasury Stock: Hidden Treasure Or Capital Misallocation? (Rating Downgrade) SA Asks: Will PayPal be acqu...

2026-02-27 09:40:41 ET Company Background Beam Therapeutics Inc. ( BEAM ) was founded by David Liu, J. Keith Joung, and Feng Zhang in 2017. Its headquarters and research hub are in Cambridge, MA, while its manufacturing hub is in Durham, NC. It is one of several gene-edi...

Immuno-Oncology Investments Accelerate as Pipeline Catalysts Multiply in 2026 Canada NewsWire Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC , Feb. 25, 2026 /CNW/ -- Equity Insider News Commentary , The immuno-oncology market is forecast to grow from $65.22 bil...

2026-02-23 14:34:32 ET More on CRISPR Therapeutics, Intellia Therapeutics Crispr Therapeutics: Very High Risk, But Even Higher Potential Reward CRISPR Therapeutics AG (CRSP) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript Crispr: Emphasis Shifts...

2026-02-23 07:46:06 ET More on ARK Invest Tracking Cathie Wood's ARK Invest 13F Portfolio - Q4 2025 Update AI Can't Sustain This Rate Of Return ARKG: Cathie Wood's Biotech Product Is In Rally Mode ETF investors cheer as Deere & Company surges 13% after ea...

2026-02-20 12:50:00 ET CRISPR Therapeutics (NASDAQ: CRSP) already has notable achievements under its belt. For instance, it developed Casgevy, a medicine for a pair of rare blood diseases, which became the first gene-editing therapy to use the famous, Nobel Prize-winning CRISPR gene...

2026-02-20 10:01:00 ET Vertex Pharmaceuticals ' (NASDAQ: VRTX) stock price is up, but its Casgevy sales partner, CRISPR Therapeutics (NASDAQ: CRSP) , is the real buy for long-term investors. Shares of Vertex, a biotech based in Boston, popped last week after it repor...

2026-02-19 18:30:00 ET If you're looking to add a bit of growth to your portfolio, you may turn to well-recognized growth companies that already generate major revenue -- or you could turn to the potential winners of tomorrow. Both types of companies make good additions. The former offers y...

2026-02-18 23:42:25 ET Investment Thesis GARP (Growth At a Reasonable Price) is by far my preferred strategy, strictly speaking about stocks, because options are much more complex and versatile. And while my stock portfolio is mostly focused on IT (hardware and software), I also loo...